Renewal Bio aims to tackle and solve several of the major health issues that modern societies face: shortage in cells, tissues, and organs for transplantation, decreasing fertility and fertility accessibility, degenerative diseases and aging. Renewal Bio is taking a novel approach to generate replacement cell therapy for human regenerative medicine and fertility. Its Research and development team is studying ex-vivo and ex-utero post-implantation embryoid models to understand the basis of gastrulation, organogenesis, and correct organ formation patterns. Moreover, the company is developing a human patient specific stem-cell derived embryoid models (SEM) grown in a controlled ex-utero device. The company believes that its approach will enable optimizing protocols for human iPSCs differentiation into many mature cell types that can be used afterwards for transplantation to treat or model human diseases and drug studies.